Patents by Inventor Kung-I Feng

Kung-I Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
    Patent number: 10167298
    Abstract: The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: January 1, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael McNevin, Yong Liu, Ian Mangion, Alfred Lee, Joyce Stellabott, Benjamin D. Sherry, Gary Martin, Kung-I Feng, Scott Schultz, Ryan Cohen, Yanfeng Zhang
  • PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF
    Publication number: 20160311834
    Abstract: The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.
    Type: Application
    Filed: October 24, 2014
    Publication date: October 27, 2016
    Inventors: Michael McNEVIN, Yong LIU, Ian MANGION, Alfred LEE, Joyce STELLABOTT, Benjamin D. SHERRY, Gary MARTIN, Kung-I FENG, Scott SHULTZ, Ryan COHEN, Yanfeng ZHANG
  • Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
    Patent number: 7919505
    Abstract: The present invention relates to the compound of the formula To methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: April 5, 2011
    Assignee: Schering Corporation
    Inventors: Pauline C. Ting, Joe F. Lee, Kung-I Feng, Michael R. Reeder, Scott T. Trzaska, Man Zhu, Chen Mao, Dimitar L. Filipov, Dimitrios N. Zarkadas
  • RAPIDLY DISINTEGRATING LYOPHILIZED ORAL FORMULATIONS OF A THROMBIN RECEPTOR ANTAGONIST
    Publication number: 20080152712
    Abstract: Disclosed is a lyophilized rapidly disintegrating solid dosage form, one embodiment of which comprises a thrombin receptor antagonist such as, or a pharmaceutically acceptable salt or hydrate thereof, a polymer such as gelatin, and a matrix forming agent such as mannitol. Systems for effectively buffering the pre-lyophilized suspension are taught, along with methods of treating patients at risk for acute coronary syndrome by administering such a rapidly disintegrating solid dosage form.
    Type: Application
    Filed: September 24, 2007
    Publication date: June 26, 2008
    Inventors: David Monteith, Enrico P. Veltri, Srinivas Duggirala, Michael Angelo Falvo, John R. Erbey, Kung-I Feng, Anastasia Pavlovsky, Suliman Chawdry
  • XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND
    Publication number: 20080027101
    Abstract: The present invention relates to the compound of the formula To methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to polymorphs and processes of synthesis of the polymorphic forms.
    Type: Application
    Filed: July 10, 2007
    Publication date: January 31, 2008
    Inventors: Pauline Ting, Joe Lee, Kung-I Feng, Michael Reeder, Scott Trzaska, Man Zhu, Chen Mao, Dimitar Filipov, Dimitrios Zarkadas